The Situation: |
Liver cancer is a leading cause of cancer deaths worldwide.1 Early detection facilitates a greater chance of survival.2 If detected early, the 5 year survival rate increases from 15% up to 70% with appropriate interventional treatment.3 |
The Challenge: |
Surveillance programs facilitate earlier cancer detection, earlier access to curative treatments and greater patient survival.2 46% of enrolled patients in surveillance programs had significant increases in 5 year survival due to early tumor detection.4 |
How We Help: |
Enhance Liver Cancer Surveillance using FUJIFILM’s AFP-L3 and DCP tests |
AFP-L3: Lectin-reactive alpha-fetoprotein; DCP: Des-gamma-carboxy prothrombin
Both biomarkers are commercially available through major US reference labs and are available for reimbursement
by Centers for Medicare & Medicaid Services (CMS)
Overview of Intended Uses (See package inserts): The μTASWako AFP-L3 and DCP test systems are in vitro devices that consist of reagents used with the μTASWako i30 Immunoanalyzer to quantitatively measure, by immunochemical techniques, AFP-L3% and DCP in human serum. Both devices are intended for IVD use as aids in the risk assessment of patients with chronic liver disease for development of HCC in conjunction with other laboratory findings, imaging studies and clinical assessment.5
Publication Number: 36363
Session Title: Liver Transplantation, Immunosuppression, Outcomes, Complications
Date and Time: November 6th (9:00 AM - 10:30 AM ET)
Talk Title: A Modified RETREAT Score Incorporating AFP-L3 and DCP Biomarkers Improves Post-Liver Transplant HCC Recurrence Risk Prognostication
Authors: Joshua S. Norman MD, Prashant Kotwani MD, Amy M Shui MA, Jennifer Dodge MPH, Francis Yao MD, Neil Mehta MD.
Publication Number: 33959
Date and Time: November 4th (12:00 PM - 1:00 PM ET)
Poster Title: Hepatocellular Carcinoma Surveillance Biomarkers Alpha-Fetoprotein-L3 And Des-Gamma-Carboxy Prothrombin In The Context Of Current Alpha-Fetoprotein Biomarker Utilization In Bridge To Liver Transplant
Authors: Mr. Michael Schneider, Dr. Kelley Nunez, Dr. Tyler Sandow, Dr. Ari J. Cohen, Dr. Paul Thevenot
References: